ClinicalTrials.gg
CompletedNCT01011959Updated Sep 30, 2013

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

A Phase 1 interventional study of REGN88 in Rheumatoid Arthritis, sponsored by Regeneron Pharmaceuticals. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-30.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
13th of 22
60 · median 88
Started
2008
with 2 others
Phase 1
7 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
4 of 22
Regeneron Pharmaceuticals

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 3 that started in 2008, is one of 7 in phase 1, and was the 1st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a randomized study of the safety and tolerability of multiple doses of REGN88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.

Read the detailed description

This is a multi-centered, randomized, double-blind, placebo-controlled, ascending parallel-group study of the safety and tolerability of REGN88 in patients with rheumatoid arthritis who are receiving concomitant methotrexate.

This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will not begin until enrollment in Part B is complete.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with an established diagnosis of Rheumatoid Arthritis
  • Patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks

Exclusion criteria

Exclusion Criteria:

  • Persistent chronic or current active infections
  • Patients who have taken anakinra within 2 weeks
  • Patients who have taken etanercept, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 4 weeks
  • Patients who have taken adalimumab within 6 weeks
  • Patients who have taken abatacept, azathioprine, cyclophosphamide or infliximab within 12 weeks
  • Patients who have taken leflunomide or rituximab within 6 months
  • Patients who have had prior treatment with tocilizumab or any other anti-IL-6 medication
  • Significant arthritis or other medical condition that could interfere with study evaluations
  • Participation in any clinical research study evaluating another drug within 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    1

    dose 1 vs. placebo

    Biological: REGN88

  • Active comparator
    2

    dose 2 vs. placebo

    Biological: REGN88

  • Active comparator
    3

    dose 3 vs. placebo

    Biological: REGN88

  • Active comparator
    4

    dose 4 vs. placebo

    Biological: REGN88

  • Active comparator
    5

    dose 5 vs. placebo

    Biological: REGN88

  • Active comparator
    6

    dose 6 vs. placebo

    Biological: REGN88

Interventions

  • BiologicalREGN88

    This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events in patients treated with REGN88 and placebo

    Time frame: 10 weeks

Secondary outcomes

  1. To evaluate exploratory efficacy endpoints

    Time frame: over 10 weeks

07

Study locations

24 sites
  • Santa Maria, California, United States
  • Boca Raton, Florida, United States
  • Clearwater, Florida, United States
  • Daytona Beach, Florida, United States
  • Delray Beach, Florida, United States
  • Palm Harbor, Florida, United States
  • Idaho Falls, Idaho, United States
  • Worcester, Massachusetts, United States
  • Lansing, Michigan, United States
  • Flowood, Mississippi, United States
  • Kalamzaoo, Missouri, United States
  • St. Louis, Missouri, United States
  • Reno, Nevada, United States
  • Charlotte, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Duncansville, Pennsylvania, United States
  • Greenville, South Carolina, United States
  • Orangeburg, South Carolina, United States
  • Hixson, Tennessee, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2009
First posted
Nov 11, 2009
Start
Dec 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Sep 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01011959
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 11, 2009
Start date
Dec 2008
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Sep 30, 2013

Study contacts

Allen Radin, MD
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion